BERNS PAUL L Insider Trading Activity

Average Profitability
12.2%
Insider Buys Quantity
1
Insider Buys Sum
$605,634.36
Insider Sells Quantity
12
Insider Sells Sum
$6.1M

Insider Activity of BERNS PAUL L

According to the SEC Form 4 filings, BERNS PAUL L, being in a position of

  1. See Remarks at Neumora Therapeutics, Inc. Common Stock,
    оver the last 12 months, has bought 0 shares, and sold 9819 shares for $34,459,
    over all time since 2025-02-18, has bought 0 shares, and sold 23690 shares for $57,927.

Biography of BERNS PAUL L

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$34,4591100

Comparison of Insiders on Amount of Buys and Sells

2026-02-17SaleNeumora Therapeutics, Inc. Common Stock
NMRA
See Remarks
9,819
0.0058%
$3.51$34,459-53.39%
2025-02-18SaleNeumora Therapeutics, Inc. Common Stock
NMRA
See Remarks
13,871
0.0083%
$1.69$23,468-4.05%
2021-08-05SaleJazz Pharmaceuticals plc
JAZZ
director
1,450
0.0025%
$154.00$223,300-3.95%
2020-11-04SaleJazz Pharmaceuticals plc
JAZZ
director
4,691
0.0081%
$150.42$705,604+3.31%
2020-08-07SaleJazz Pharmaceuticals plc
JAZZ
director
931
0.0017%
$125.87$117,185+29.08%
2019-08-09SaleJazz Pharmaceuticals plc
JAZZ
director
726
0.0013%
$135.65$98,481-9.37%
2018-08-10SaleJazz Pharmaceuticals plc
JAZZ
director
660
0.0011%
$176.61$116,563-21.48%
2017-08-11SaleJazz Pharmaceuticals plc
JAZZ
director
662
0.0011%
$142.37$94,248+4.2%
2016-08-15SaleJazz Pharmaceuticals plc
JAZZ
director
633
0.001%
$136.45$86,373-2.62%
2016-04-20PurchaseCellectar Biosciences, Inc.
CLRB
director
234,742
6.8256%
$2.58$605,634+12.2%
2015-08-10SaleJazz Pharmaceuticals plc
JAZZ
director
1,602
0.0026%
$180.00$288,355-22.09%
2014-08-12SaleJazz Pharmaceuticals plc
JAZZ
director
2,174
0.0036%
$133.15$289,468+30.62%
2013-08-13SaleJazz Pharmaceuticals plc
JAZZ
director
2,140
0.0037%
$81.86$175,180+65.54%
2012-03-09SaleJazz Pharmaceuticals plc
JAZZ
director
78,400
0.1481%
$49.56$3.89M+3.47%
Total: 14
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.